Corpusense

Idexx Laboratories (IDXX) earnings call transcript summary & sentiment

Last call Tue 4 Aug 2026·Next Tue 3 Nov 2026

Our read on the 4 August 2026 earnings call

Overall tone: Positive

Overall tone

Positive

Executive Summary

IDEXX Laboratories reported strong Q2 2026 financial results, highlighted by 9% organic revenue growth and a 15% comparable EPS increase to $4.27.

Core Signals

Revenue Growth & Demand: Organic revenue grew 9% year-over-year in Q2, driven by a 10.3% organic gain in CAG Diagnostics recurring revenues, 13% growth in Water, and 9% growth in LPD.

Bullish Signals

CAG Diagnostics recurring revenue grew 10.3% organically in Q2, outpacing U.S. clinical visit trends by approximately 1,100 basis points.

Risk Signals

U.S. same-store clinical visits fell 1.3% in Q2, with wellness visits dropping 3.4% due to ongoing macroeconomic pressure on pet owners.

Q&A Signals

Repeated analyst topics: Analysts repeatedly questioned clinical visit trends, second-half margin dynamics given planned growth investments, and InView DX placement trajectories.

Key Investor Debate

The primary investor debate centers on IDEXX's ability to maintain double-digit CAG recurring revenue growth against a backdrop of ongoing clinical visit declines, particularly in discretionary wellness visits.

Analyst Takeaway

IDEXX demonstrated that its multi-modality diagnostic platform can compound growth through pricing power, new account conversions, and rising test utilization per visit regardless of clinical traffic.

Those are the opening lines. The full read covers the whole earnings transcript: every bullish and bearish signal, what analysts pressed hardest on, and where management answered vaguely — each with the quote behind it. Every line sourced.

See the full Earnings Highlight

Themes across Idexx Laboratories and the Health Care sector

Analyse a theme over quarters — what's brand new, what's being talked about more, and what is spreading to more companies across the sector.

Unlock themes

Ask about Idexx Laboratories's earnings, or other S&P 500 earnings calls

Ask across the corpus, instead of reading one call at a time. Scope it to Idexx Laboratories, its sector, or every name we cover — plain English, no operators — and answers come back structured: a summary, the drivers, and a read on each company.

"What did Idexx Laboratories say about margins, and did the framing change from last quarter?"

"Did Idexx Laboratories's management walk back any full-year guidance, and how did they frame it?"

"Where did Idexx Laboratories avoid answering on capital allocation?"

Unlock search

Earnings call history & sentiment

Every one at 08:30 ET, before the open.

Date Day Period Corpusense read
2026-08-04Tuesday2026 Q3Positive
2026-05-05Tuesday2026 Q2Positive
2026-02-02Monday2026 Q1Positive
2025-11-03Monday2025 Q4—
2025-08-04Monday2025 Q3—
2025-05-01Thursday2025 Q2—
2025-02-03Monday2025 Q1—

Earnings calls across Health Care Equipment & Supplies

The companies Idexx Laboratories is read alongside. Each has its own earnings call dates and sentiment.

ABTAbbott LaboratoriesALGNAlign TechnologyBAXBaxter InternationalBDXBecton DickinsonBSXBoston ScientificCOOCooper Companies (The)DXCMDexcomEWEdwards Lifesciences

Idexx Laboratories is one of the S&P 500 companies we track

Sentiment analysis on any single earnings call, themes building across a sector, and search across every company and quarter — each claim linked back to the passage it came from.

Create a free account See the full calendar Plans & pricing